Skip to main content

Want a detailed portfolio tracker?

AVTX
NASDAQ
$18.21

Avalo Therapeutics Inc (AVTX)

Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved diseases, particularly those related to immunological regulation. With a robust pipeline of proprietary drug candidates, Avalo is dedicated to addressing critical unmet medical needs in areas where effective treatments remain scarce. Leveraging in-depth insights into disease mechanisms alongside a rigorous clinical trial methodology, the company is well-positioned to achieve significant advancements in patient care. Through its patient-centric approach, Avalo not only seeks to improve therapeutic outcomes but also aims to make a substantial impact on the lives of those it serves, establishing itself as a noteworthy player in the biopharmaceutical landscape.
Website: https://www.avalotx.com
Sector:
Healthcare
Industry:
Biotechnology
68 analysts
Buy
Target: $44.69 (+145.41%)

Market Cap

$404M

Free Cash Flow Yield

-12.74%

Beta (5Y)

0.53

Price Chart

Valuation
Market Cap$404M
P/S9875.25
P/B3.78
Profitability
Total Revenue (TTM)$59K
Gross Profit (TTM)-$40M
EBITDA-$73M
Operating Margin-33461%
EPS-$5.59
Financial Health
Free Cash Flow Yield-12.74%
Growth & Risk
Revenue 5Y CAGR-61.39%
FCF 5Y CAGR+16.88%
Beta (5Y)0.53
Sharpe Ratio1.67